Dr. Oefelein is a board certified physician and a Fellow of the American College of Surgeons with extensive experience (> 20 year) in the pharmaceutical and the device industry—including dermatology, urology, oncology, ophthalmology and plastic and bariatric surgery. He has authored nearly 100 peer reviewed publications, and he has delivered numerous scientific presentations at regional, national and international venues. He has designed and executed clinical trials for a number of purposes, including: registration, differentiation, pharmaco- economic, value, label change, safety, drug-drug interaction, dose-ranging, IND/NDA and IDE/PMA. Dr. Oefelein has develop several Genitourinary oncology drugs: Degarelix, Zometa and Apaziquone, LiPax and non-oncology drugs: TesoRx, Levaquin, Botox, Serenity-120. He is an active member of numerous medical societies, including the Society of Urological Oncology, SUFU, AUA, American College of Surgeons and Laparoscopic surgeons. Dr. Oefelein has led several device (Silicone breast implants, Lap-Band) and pharmaceutical (Bimatoprost, Latisse, Sanctura XR) safety evaluations. Dr Oefelein has developed scientific content for, and he has led, numerous advisory board meetings, and he has translated the meeting output into enduring materials. He has developed numerous publication and differentiation plans for a wide range of pharmaceutical and device assets. In summary, Dr. Oefelein has diverse academic, pharmaceutical and device experiences, and a track record of success.